Evolva Holding (ELVAF) 0.7239 $ELVAF
Skin And Skin Structure Infections (SSSI) Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Opportunities
M2 - Fri Dec 11, 3:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/gm2zpr/skin_and_skin) has announced the addition of the "Skin And Skin Structure Infections (SSSI) Global Clinical Trials Review, H2, 2015" report to their offering. Our clinical trial report, Skin And Skin Structure Infections (SSSI) Global Clinical Trials Review, H2, 2015" provides an overview of Skin And Skin Structure Infections (SSSI) clinical trials scenario. This report provides top line data relating to the clinical trials on Skin And Skin Structure Infections (SSSI). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Allergan Plc - Merck & Co., Inc. - Nabriva Therapeutics AG - The Medicines Company - AstraZeneca Plc - Evolva Holding SA - Pfizer Inc. - Laboratory Corporation of America Holdings - Bayer AG For more information visit http://www.researchandmarkets.com/research/gm...n_and_skin
AGN: 235.05 (-2.24), PFE: 34.22 (-0.53), MRK: 55.89 (-1.61), AZN: 27.58 (-0.05), LH: 125.70 (-1.65), NBRV: 7.63 (+0.21)
Evolva announces launch of valencene
M2 - Mon Dec 07, 5:58AM CST
Evolva Holding SA (SIX:EVE) announced today the launch of valencene, a highly prized orange flavour and fragrance (F&F) ingredient.
Global Stevia / Stevia Rebaudiana Market (2014-2020):
M2 - Thu Feb 05, 4:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/38bljk/global_stevia_) has announced the addition of the "Global Stevia / Stevia Rebaudiana Market (2014-2020): " report to their offering. The report focuses on the market revenue generated by the sale and usage of stevia as a standalone product or as part of food type. The different end use market applications which are in the scope of the report include products from the food industry, beverages industry, processed food, confectionery food, surface and dressing food, dietary supplements and others. Dairy foods, bakery, bottled and canned food and snacks are further analyzed in the food industry segment. Rebaudioside A and Stevioside are the key functional or sweetening ingredient considered in the market scope. The stevia extracts are generally of different forms or types like liquid extracts, powdered extracts and stevia leaves. The different end use applications were also analyzed by the different geographic regions and key countries in the report. Revenues and the volumes of stevia are provided for the period 2013- 2020, covering all the market product segmentation in the report. Key Topics Covered: 1 Stevia market overview 2 Executive Summary 3 Global Stevia Market - Market Forces 4 Stevia Market Competitive Landscape 5 Sugar Substitutes Market overview 6 Stevia Market 7 Global Stevia Market - By End User Applications 8 Geographic analysis for Stevia - By End- Users/Industries/Applications 9 Global Stevia Delivery Market -Geographic Analysis 10 Market Entropy 11 Company Profiles 12 Appendix 13 About Us Companies Mentioned: - Cargill Inc. - Cumberland Packing Corp. - Evolva Holding SA - Groupe DANONE - Ingredion Inc. - Whole Earth Sweetener Company Llc - Mulder Natural Foods N.V - Nature's Bounty Inc. - Nestle S.A - Odwalla Inc - Pepsi Co. - Pure Circle Ltd - S&W Seed Company - Stevia Corp - Sunwin Stevia International Inc. - Sweet Green Fields LLC - Sweetlife Stevia Sweetener - Tate & Lyle plc - White Wave Foods Co. - Whole Earth Sweetener Co. - Wild Flavors Inc. - Xinghua Green Biological Preparation Co. Ltd. - GLG Life Tech Corporation - Stevia First Corporation For more information visit http://www.researchandmarkets.com/research/38...al_stevia_
SANW: 4.25 (+0.07)
Evolva and Cargill to Collaborate on Second Family of Ingredients
BusinessWire - Mon Jan 19, 12:01AM CST
Evolva Holding SA ("Evolva"; SIX:EVE) and Cargill have signed an agreement to co-develop a sustainable, customisable, and cost-effective fermentation production process for a second family of high-value food and beverage ingredients.
Evolva disposes EV-035 series programme to Emergent BioSolutions
M2 - Thu Dec 18, 4:59AM CST
Evolva Holding SA (SIX:EVE), a health, wellness and nutrition company, announced on Wednesday the acquisition by Emergent BioSolutions Inc (NYSE:EBS) of Evolva's anti-bacterial programme, the EV-035 series.
EBS: 38.97 (-2.11)
Evolva Sells EV-035 Series to Emergent BioSolutions
BusinessWire - Wed Dec 17, 12:01AM CST
Evolva Holding SA ("Evolva", SIX:EVE) today announced that Emergent BioSolutions Inc. ("Emergent", NYSE:EBS) has acquired Evolva's anti-bacterial programme, the EV-035 series. The lead compound in the EV-035 series is the broad-spectrum antibiotic GC-072, which is being developed with US government biodefense funding. For Evolva, this transaction is worth up to USD 70.5 million plus royalties.
EBS: 38.97 (-2.11)
Evolva to Acquire Allylix
BusinessWire - Tue Nov 18, 12:01AM CST
--Cargill to increase stake in Evolva
Skin And Skin Structure Infections (SSSI) Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Opportunities
M2 - Fri Dec 11, 3:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/gm2zpr/skin_and_skin) has announced the addition of the "Skin And Skin Structure Infections (SSSI) Global Clinical Trials Review, H2, 2015" report to their offering. Our clinical trial report, Skin And Skin Structure Infections (SSSI) Global Clinical Trials Review, H2, 2015" provides an overview of Skin And Skin Structure Infections (SSSI) clinical trials scenario. This report provides top line data relating to the clinical trials on Skin And Skin Structure Infections (SSSI). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Allergan Plc - Merck & Co., Inc. - Nabriva Therapeutics AG - The Medicines Company - AstraZeneca Plc - Evolva Holding SA - Pfizer Inc. - Laboratory Corporation of America Holdings - Bayer AG For more information visit http://www.researchandmarkets.com/research/gm...n_and_skin
AGN: 235.05 (-2.24), PFE: 34.22 (-0.53), MRK: 55.89 (-1.61), AZN: 27.58 (-0.05), LH: 125.70 (-1.65), NBRV: 7.63 (+0.21)
Evolva announces launch of valencene
M2 - Mon Dec 07, 5:58AM CST
Evolva Holding SA (SIX:EVE) announced today the launch of valencene, a highly prized orange flavour and fragrance (F&F) ingredient.
Global Stevia / Stevia Rebaudiana Market (2014-2020):
M2 - Thu Feb 05, 4:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/38bljk/global_stevia_) has announced the addition of the "Global Stevia / Stevia Rebaudiana Market (2014-2020): " report to their offering. The report focuses on the market revenue generated by the sale and usage of stevia as a standalone product or as part of food type. The different end use market applications which are in the scope of the report include products from the food industry, beverages industry, processed food, confectionery food, surface and dressing food, dietary supplements and others. Dairy foods, bakery, bottled and canned food and snacks are further analyzed in the food industry segment. Rebaudioside A and Stevioside are the key functional or sweetening ingredient considered in the market scope. The stevia extracts are generally of different forms or types like liquid extracts, powdered extracts and stevia leaves. The different end use applications were also analyzed by the different geographic regions and key countries in the report. Revenues and the volumes of stevia are provided for the period 2013- 2020, covering all the market product segmentation in the report. Key Topics Covered: 1 Stevia market overview 2 Executive Summary 3 Global Stevia Market - Market Forces 4 Stevia Market Competitive Landscape 5 Sugar Substitutes Market overview 6 Stevia Market 7 Global Stevia Market - By End User Applications 8 Geographic analysis for Stevia - By End- Users/Industries/Applications 9 Global Stevia Delivery Market -Geographic Analysis 10 Market Entropy 11 Company Profiles 12 Appendix 13 About Us Companies Mentioned: - Cargill Inc. - Cumberland Packing Corp. - Evolva Holding SA - Groupe DANONE - Ingredion Inc. - Whole Earth Sweetener Company Llc - Mulder Natural Foods N.V - Nature's Bounty Inc. - Nestle S.A - Odwalla Inc - Pepsi Co. - Pure Circle Ltd - S&W Seed Company - Stevia Corp - Sunwin Stevia International Inc. - Sweet Green Fields LLC - Sweetlife Stevia Sweetener - Tate & Lyle plc - White Wave Foods Co. - Whole Earth Sweetener Co. - Wild Flavors Inc. - Xinghua Green Biological Preparation Co. Ltd. - GLG Life Tech Corporation - Stevia First Corporation For more information visit http://www.researchandmarkets.com/research/38...al_stevia_
SANW: 4.25 (+0.07)
Evolva and Cargill to Collaborate on Second Family of Ingredients
BusinessWire - Mon Jan 19, 12:01AM CST
Evolva Holding SA ("Evolva"; SIX:EVE) and Cargill have signed an agreement to co-develop a sustainable, customisable, and cost-effective fermentation production process for a second family of high-value food and beverage ingredients.
Evolva disposes EV-035 series programme to Emergent BioSolutions
M2 - Thu Dec 18, 4:59AM CST
Evolva Holding SA (SIX:EVE), a health, wellness and nutrition company, announced on Wednesday the acquisition by Emergent BioSolutions Inc (NYSE:EBS) of Evolva's anti-bacterial programme, the EV-035 series.
EBS: 38.97 (-2.11)
Evolva Sells EV-035 Series to Emergent BioSolutions
BusinessWire - Wed Dec 17, 12:01AM CST
Evolva Holding SA ("Evolva", SIX:EVE) today announced that Emergent BioSolutions Inc. ("Emergent", NYSE:EBS) has acquired Evolva's anti-bacterial programme, the EV-035 series. The lead compound in the EV-035 series is the broad-spectrum antibiotic GC-072, which is being developed with US government biodefense funding. For Evolva, this transaction is worth up to USD 70.5 million plus royalties.
EBS: 38.97 (-2.11)
Evolva to Acquire Allylix
BusinessWire - Tue Nov 18, 12:01AM CST
--Cargill to increase stake in Evolva
